3 Stocks Pushing The Health Care Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Health Care sector as a whole closed the day down 0.5% versus the S&P 500, which was up 0.1%. Laggards within the Health Care sector included Aoxing Pharmaceutical ( AXN), down 2.9%, Semler Scientific ( SMLR), down 2.8%, Reliv' International ( RELV), down 7.9%, Dynatronics ( DYNT), down 1.9% and Vision-Sciences ( VSCI), down 3.6%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the sector lower today:

Vision-Sciences ( VSCI) is one of the companies that pushed the Health Care sector lower today. Vision-Sciences was down $0.04 (3.6%) to $1.07 on light volume. Throughout the day, 6,131 shares of Vision-Sciences exchanged hands as compared to its average daily volume of 27,800 shares. The stock ranged in price between $1.07-$1.14 after having opened the day at $1.07 as compared to the previous trading day's close of $1.11.

Vision-Sciences has a market cap of $54.2 million and is part of the drugs industry. Shares are up 11.0% year-to-date as of the close of trading on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Reliv' International ( RELV) was down $0.12 (7.9%) to $1.40 on heavy volume. Throughout the day, 91,056 shares of Reliv' International exchanged hands as compared to its average daily volume of 12,900 shares. The stock ranged in price between $1.40-$1.64 after having opened the day at $1.52 as compared to the previous trading day's close of $1.52.

Reliv' International, Inc. develops, manufactures, and markets nutritional supplements that promote basic nutrition, weight loss, athletic performance, digestive health, women's health, anti-aging, and healthy energy. Reliv' International has a market cap of $15.8 million and is part of the drugs industry. Shares are down 45.9% year-to-date as of the close of trading on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Reliv' International as a hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

Highlights from TheStreet Ratings analysis on RELV go as follows:

  • The gross profit margin for RELIV INTERNATIONAL INC is currently very high, coming in at 81.71%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -1.04% trails the industry average.
  • RELV's debt-to-equity ratio is very low at 0.27 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.82 is somewhat weak and could be cause for future problems.
  • RELV, with its decline in revenue, underperformed when compared the industry average of 0.2%. Since the same quarter one year prior, revenues fell by 23.3%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Personal Products industry and the overall market, RELIV INTERNATIONAL INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to -$1.36 million or 324.34% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.

You can view the full analysis from the report here: Reliv' International Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Aoxing Pharmaceutical ( AXN) was another company that pushed the Health Care sector lower today. Aoxing Pharmaceutical was down $0.01 (2.9%) to $0.38 on light volume. Throughout the day, 25,573 shares of Aoxing Pharmaceutical exchanged hands as compared to its average daily volume of 37,400 shares. The stock ranged in price between $0.36-$0.42 after having opened the day at $0.36 as compared to the previous trading day's close of $0.39.

Aoxing Pharmaceutical Company, Inc., a specialty pharmaceutical company, researches, develops, manufactures, and distributes various narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. Aoxing Pharmaceutical has a market cap of $20.0 million and is part of the drugs industry. Shares are up 56.5% year-to-date as of the close of trading on Wednesday.

TheStreet Ratings rates Aoxing Pharmaceutical as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on AXN go as follows:

  • Net operating cash flow has decreased to -$4.35 million or 41.91% when compared to the same quarter last year. Despite a decrease in cash flow of 41.91%, AOXING PHARMACEUTICAL CO INC is in line with the industry average cash flow growth rate of -47.88%.
  • AOXING PHARMACEUTICAL CO INC has improved earnings per share by 20.0% in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, AOXING PHARMACEUTICAL CO INC reported poor results of -$0.34 versus -$0.32 in the prior year.
  • 43.50% is the gross profit margin for AOXING PHARMACEUTICAL CO INC which we consider to be strong. Despite the high profit margin, it has decreased significantly from the same period last year. Despite the mixed results of the gross profit margin, AXN's net profit margin of -74.48% significantly underperformed when compared to the industry average.
  • Investors have driven up the company's shares by 71.65% over the past year, a rise that has exceeded that of the S&P 500 Index. Regarding the future course of this stock, we feel that the risks involved in investing in AXN do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 29.8% when compared to the same quarter one year prior, rising from -$2.60 million to -$1.82 million.

You can view the full analysis from the report here: Aoxing Pharmaceutical Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

3 Stocks Pushing The Health Services Industry Lower

3 Stocks Pushing The Health Services Industry Lower

3 Stocks Pushing The Health Services Industry Lower

3 Stocks Pushing The Health Services Industry Lower

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

3 Health Care Stocks Pushing The Sector Higher

3 Health Care Stocks Pushing The Sector Higher